Harmony Biosciences Completes Acquisition of Zynerba Pharmaceuticals And Expands Pipeline
DEVON, Pa., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan...
DEVON, Pa., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan...
DEVON, Pa., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan...
Harmony is paying $60 million in cash for Zynerba, with another $140 million on the table in the form of a contingent value right (CVR) if Zygel makes it through development and registration as predicted and meets various sales targets, including an aggregate of $500 million net revenues by mid-2025.
(RTTNews) - Harmony Biosciences Holdings Inc. (HRMY) said that it agreed to acquire Zynerba Pharmaceuticals Inc. (ZYNE), a leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, including Fragile X syndrome.
DEVON, Pa., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) (the œCompany), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for...
DEVON, Pa., July 25, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) (the “Company”), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for...
Annual Meeting Reconvened and Adjourned Without Conducting Business Meeting to Reconvene on July 27, 2023 at 9:00 am EDT DEVON, Pa., June 28, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc....